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The Effect of Single Dose Methylphenidate on Neurometabolites according to 
COMT Gene Val158Met Polymorphism in the Patient with Attention Deficit 
Hyperactivity Disorder: A Study Using Magnetic Resonance Spectroscopy
Onder Ozturk1, Huseyin Alacam2, Burge Kabukcu Basay1, Omer Basay1, Ahmet Buber1, Ozlem Izci Ay3, 
Kadir Agladıoglu4, Mehmet Emin Erdal3,*, Hasan Herken2,*
1Department of Child and Adolescent Psychiatry, 2Department of Psychiatry, 4Department of Radiology, Medical Faculty, Pamukkale 
University, Denizli, 3Department of Medical Biology and Genetics, Medical Faculty, Mersin University, Mersin, Turkey
Objective: Attention deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder. Thus, the present study 
aimed to determine the effects of a single dose of methylphenidate (Mph) on neurometabolite levels according to polymorphisms 
of the catechol-O-methyltransferase (COMT) gene.
Methods: This study evaluated the neurometabolite levels including N-acetylaspartate (NAA), creatine (Cr), and choline (Cho) 
of ADHD patients, before and after treatment with Mph (10 mg) according to the presence of COMT polymorphisms. The spectra 
were obtained from the dorsolateral prefrontal cortex (DLPFC), anterior cingulate cortex (ACC), cerebellum, and striatum.
Results: The NAA levels of the val/val and val genotype carriers (val/val and val/met genotypes) increased in the DLPFC and 
ACC, respectively, following Mph treatment. The NAA/Cr ratio was lower in the DLPFC of val carriers than in the met/met genotype 
carriers prior to Mph administration. The Cho levels of the val/met genotype and val carriers increased in the striatum following 
Mph treatment. Following Mph treatment, the Cr levels of the met/met genotype carriers were higher than those of the val/met 
genotype and val carriers. Additionally, after Mph treatment, there was a significant increase in Cr levels in the DLPFC of the 
met/met genotype carriers but a significant decrease in such levels in the striatum of val/val genotype carriers.
Conclusion: These findings suggest that polymorphisms of the COMT gene can account for individual differences in neuro-
chemical responses to Mph among ADHD patients. Therefore, further studies are needed to fully characterize the effects of 
the Val158met polymorphism of the COMT gene on treatment outcomes in patients with ADHD.
KEY WORDS: Catechol-O-methyltransferase; Neurometabolite; Attention deficit disorder with hyperactivity; Methylphenidate.
INTRODUCTION
Attention deficit hyperactivity disorder (ADHD) is a 
neurodevelopmental disorder that manifests during child-
hood and is characterized by attentional problems and/or 
hyperactivity-impulsivity in varying degrees of severity; 
it has a worldwide pooled prevalence of 5.29%.1) ADHD 
is a chronic disorder that negatively affects several di-
mensions of life, particularly the academic, occupational, 
and social domains, during both childhood and adul-
thood.2) In terms of its etiology, there are disruptions of the 
dopaminergic and noradrenergic pathways, which regu-
late attention, and an inhibition of executive function via 
alterations of the cortico–striato–thalamic–cortical net-
works.3,4)
The genetic heritability of ADHD ranges from 70% to 
90%,2,5,6) and a number of studies have investigated candi-
date genes that may contribute to the manifestation of 
ADHD. The catechol-O-methyltransferase (COMT) gene, 
which plays a role in the removal of dopamine (DA) from 
the synaptic space, is frequently studied as a possible can-
didate gene.7) A single nucleotide polymorphism (SNP) of 
the COMT gene that includes a guanine (G) to adenine (A) 
mutation at codon 158 results in an amino acid sub-
stitution of methionine (met) for valine (val) during en-
zyme synthesis.8) This polymorphism, which is known as 
either Val158Met or rs4680,8) results in an enzyme with 
two Val alleles (val/val genotype) that is more thermo-
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stable9) and degrades DA three-to-four times more rapidly 
than the two met isoforms (met/met genotypes) which, in 
turn, results in lower levels of DA in the synaptic space.8)
Heterozygotes (val/met genotype carriers) are asso-
ciated with intermediate levels of COMT activity,10,11) and 
healthy met/met genotype carriers exhibit superior per-
formance in a number of cognitive paradigms, including 
the letter-number-sequencing test12) and n-back task,13) 
compared with individuals with the val/val genotype. The 
Val allele is related to decreased prefrontal cortical activa-
tion in healthy adults14) and impaired working memory 
function in healthy adults and children.14,15) Cheon et al.16) 
evaluated the association between the Val158met poly-
morphism and treatment response and found that the re-
sponse to methylphenidate (Mph) was better in val/val 
genotype carriers than in carriers of other genotypes. 
However, Bellgrove et al.17) observed that children with 
ADHD carrying the val/val genotype exhibited superior 
sustained attention than met carriers (met/met and val/met 
genotypes). On the other hand, studies of the relationship 
between the etiology of ADHD and polymorphisms of the 
COMT gene have reported equivocal results. For exam-
ple, Kereszturi et al.18) reported that the Val allele is more 
common in children with ADHD than in healthy controls, 
whereas other studies19-21) and meta-analyses22,23) did not 
observe any type of relationship between these variables. 
1H magnetic resonance spectroscopy (1H MRS) is a 
non-invasive neuroimaging technique that can be used in 
vivo to assess levels of neurometabolites, such as N-acety-
laspartate (NAA), creatine (Cr), and choline (Cho), in a 
variety of brain areas. Courvoisie et al.24) found higher 
levels of Cho in the prefrontal cortex (PFC) of children di-
agnosed with ADHD compared with healthy controls. 
Similarly, Husarova et al.25) assessed children with 
ADHD during the second month of atomoxetine treatment 
and identified decreases in NAA levels and the NAA/Cr 
ratio in the left dorsolateral PFC (DLPFC) in conjunction 
with an increase in the Cho/Cr ratio in the right DLPFC. 
Amor26) reported that drug-naïve children with a diagnosis 
of ADHD had lower Cho levels in the left PFC compared 
with healthy controls and ADHD children who had re-
ceived treatment. A meta-analysis conducted by Aoki et 
al.27) showed that, although the results of the adult ADHD 
patients and controls were similar, the NAA levels of 
ADHD-diagnosed children were higher than those of 
healthy controls in the medial PFC area. Thus, the present 
authors speculated that age-related changes in ADHD 
symptoms may have a neuronal basis even though no sig-
nificant alterations in other metabolites have been 
reported.
Therefore, the present study utilized 1H MRS to inves-
tigate alterations in the neurometabolite levels of adult 
ADHD patients following a single dose of Mph according 
to the presence of the Val158met polymorphism of the 
COMT gene. To the best of our knowledge, the present 
study is the first to investigate pre- and post-Mph neuro-
metabolite levels in adult ADHD patients based on this 
COMT polymorphism. It was hypothesized that different 
COMT gene polymorphism carriers would exhibit differ-
ent treatment outcomes in terms of neurometabolite levels 
in different brain regions following a single dose of Mph.
METHODS
Subject Characteristics 
The present study assessed 57 adult patients who were 
between 18 and 60 years of age and who met the criteria of 
the Diagnostic and Statistical Manual of Mental Disorders 
4th edition, text revision (DSM-IV-TR) for ADHD.28) All
patients were recruited from the psychiatry outpatient 
clinic of Pamukkale University in Turkey, and the absence 
of other psychiatric diagnoses was confirmed by struc-
tured interviews using the Turkish version of the Structur-
ed Clinical Interview for DSM-IV Clinical Version 
(SCID-I CV).29) Additionally, the Turkish version of an 
adult attention-deficit  disorder (ADD)/ADHD DSM-IV- 
based diagnostic screening and rating scale was used to as-
sess the patients.30) Patients with a neurodegenerative dis-
order, such as Alzheimer’s disease or Parkinson’s disease, 
and/or a clinical evaluation of an intellectual disability 
were excluded from the present study. The local Ethics 
Committee of Pamukkale University approved the study 
protocol (approval no. 60116787/020/27537), and all pa-
tients were informed of the aim of the study and its proce-
dures; all patients also provided written informed consent 
confirming their voluntary participation in this study.
All patients were examined with a single-voxel 1H 
MRS, and the spectra were obtained from the DLPFC, an-
terior cingulate cortex (ACC), striatum, and cerebellum 
via a clinical 1.5-T magnetic resonance scanner (GE 
Medical System, Milwaukee, WI, USA). For this proce-
dure, the following parameters were employed: a point-re-
solved spectroscopy sequence with water suppression, a 
chemical shift selective imaging sequence, an echo time 
(TE)/repetition time (TR) ratio of 35/3,000 ms, and 128 
averages. Additionally, the present study utilized a con-
ventional spin-echo sequence with T2-weighted fast 
spin-echo parameters as follows: horizontal slices (10-mm 
186 O. Ozturk, et al.
Table 1. Sociodemographic characteristics
Characteristic Data
Sex
  Female 12 (21.1)
  Male 45 (78.9)
Marital status
  Single 35 (61.4)
  Married 18 (31.6)
  Divorced 4 (7.0)
Education
  Primary education 5 (8.8)
  High school 12 (21.1)
  University 40 (70.1)
Methylphenidate use
  Yes 33 (57.9)
  No 24 (42.1)
Values are presented as number (%).
thick), a TR/TE ratio of 3,000/88 ms, a field of view of 10 
cm, and a 512×512 matrix. The entire MR session took ap-
proximately 45 minutes to complete.
Patients who had been previously been administered 
Mph discontinued their use of the medication 48 hours pri-
or to the initiation of the neuroimaging procedures. The 
levels of NAA, Cho, and Cr in the DLPFC, ACC, striatum, 
and cerebellum were examined using single-voxel 1H 
MRS when the patients were medication-naïve 30 mi-
nutes after the administration of Mph (10 mg).
Genotypic Analysis of the Val158Met (c.1947, G＞A, 
rs4680) Polymorphism of the COMT Gene 
DNA extraction 
A venous blood sample was obtained from each in-
dividual and collected in a tube containing ethylene-
diaminetetraacetic acid. The DNA was extracted from the 
whole blood using a previously described salting-out 
procedure.31) 
Genotype determination 
The genotypes were determined using a TaqManTM flu-
orogenic 5’-nuclease assay and TaqMan probes (Applied 
Biosystems, Framingham, MA, USA). The Primer Ex-
press 3.0 software package (Applied Biosystems) was 
used to design both the polymerase chain reaction (PCR) 
primers and the TaqMan probes. The following custom- 
made primers and probes were used for the COMT gene 
1947 G＞A Val158Met (rs4680) allele; forward primer: 
5’-CATCACCCAGCGGATGGT-3’, reverse primer: 5’- 
TCAGGCATGCACACCTTGTC-3’, probe: (A)5’-VIC- 
ATTTCGCTGGCATGAA-NFQ-MGB-3’, and probe: (G) 
5’-FAM-ATTTCGCTGGCGTGAA-NFQ-MGB-3’ (App-
lied Biosystems). 
The SNP amplification assays were performed accord-
ing to the manufacturer’s instructions (Applied Biosys-
tems). Briefly, 25 μl of the reaction solution that con-
tained 30 ng of DNA was mixed with 12.5 μl of 2× 
TaqMan Universal PCR Master Mix (Applied Biosys-
tems), 900 nmol of each primer, and 200 nmol of each 
probe. The reaction conditions were as follows: pre-in-
cubation at 60oC for 1 minute, incubation at 95oC for 10 
minutes, 40 cycles at 95oC for 15 seconds, and then in-
cubation at 60oC for 1 minute. The amplifications and 
analyses were performed using an ABI Prism 7500 
Real-Time PCR System (Applied Biosystems) with the 
SDS software package (ver. 2.0.6; Applied Biosystems) 
for allelic discrimination.31) 
Statistical Analysis
All data were analyzed using the SPSS for Windows 
software package (ver. 17.0; SPSS Inc., Chicago, IL, 
USA). Categorical variables were compared using Pear-
son’s chi-square (χ2) tests, and the distribution of the nu-
meric variables was evaluated using the Kolmogorov- 
Smirnov test. Nonparametric tests were used because the 
variables were not distributed normally. Kruskal-Wallis 
tests were used to make comparisons among the three 
groups, and Mann-Whitney U-tests were used to compare 
the data between two groups. Significant differences in 
the changes in neurometabolite levels prior to and after 
treatment with Mph were assessed with the Wilcoxon 
two-related-samples test, and a p value ＜0.05 was con-
sidered to indicate statistical significance. 
RESULTS
Of the 57 adult ADHD patients assessed in the present 
study, 12 were female (21.1%) and 45 were male (78.9%); 
all were between 18 and 60 years of age (mean age, 
29.05±7.85 years). However, only 33 (57.9%) of the pa-
tients had been receiving Mph for the treatment of ADHD 
(Table 1).
The COMT polymorphism and ADHD subtype dis-
tributions of the patients are shown in Table 2. The dis-
tribution of the three genotypes for the COMT gene was in 
agreement with the expected values of the Hardy- 
Weinberg equilibrium (p=0.888). The majority of the pa-
tient group (80.7%; n=46) were val carriers (val/val, 
val/met), that is, rapid metabolizers. There were no sig-
nificant differences in the distributions of the ADHD sub-
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Table 3. Comparison of the neurometabolites between the COMT gene Val158Met polymorphism groups 
Val/val Val/met Met/met p value* p value†
Comparison of NAA levels before and after Mph
  DLPFC Before Mph 68 (50-117)† 66 (45-98) 74 (53-107) 0.486 0.04†
After Mph 71 (51-115)
†
59.5 (39-92) 70 (60-113) 0.097
  ACC Before Mph 62.5 (51-126) 58 (39-87) 66 (51-83) 0.174
After Mph 68.5 (54-113) 63 (47-94) 62 (56-79) 0.225
  Striatum Before Mph 63.5 (50-97) 62 (45-82) 61 (52-76) 0.684
After Mph 67 (45-94) 59 (45-85) 68 (55-105) 0.146
  Cerebellum Before Mph 61 (38-96) 60.5 (31-78) 57 (37-89) 0.724
After Mph 66 (38-85) 60.5 (38-84) 61 (52-88) 0.521
Comparison of Cho levels before and after Mph
  DLPFC Before Mph 41 (26-66) 38 (29-62) 37 (26-52) 0.196
After Mph 42 (29-70) 39.5 (26-62) 40 (36-51) 0.170
  ACC Before Mph 38.5 (24-65) 37 (25-50) 38 (22-54) 0.945
After Mph 41 (24-44) 37.5 (26-52) 35 (32-48) 0.405
  Striatum Before Mph 36 (24-53) 33 (22-45)
†
36 (28-55) 0.239 0.01
†
After Mph 36.5 (27-57) 35.5 (27-56)† 36 (26-47) 0.929
  Cerebellum Before Mph 45.5 (31-61) 40.5 (25-51) 45 (25-59) 0.196
After Mph 41 (27-64) 41.5 (29-56) 44 (31-64) 0.492
Comparison of Cr levels before and after Mph
  DLPFC Before Mph 40 (29-70) 40.5 (29-53) 39 (28-55)† 0.804 0.01†
After Mph 43 (33-69) 39 (23-60)* 42 (38-66)*
,†
0.018*
  ACC Before Mph 41.5 (29-73) 40.5 (30-57) 43 (36-49) 0.357
After Mph 44 (31-69) 42.5 (33-62) 43 (34-55) 0.591
  Striatum Before Mph 47.5 (36-69)
†
42 (29-51) 46 (38-59) 0.054 0.01
†
After Mph 43 (34-66)† 41.5 (34-58) 48 (36-61) 0.463
  Cerebellum Before Mph 53 (24-70) 49 (34-66) 54 (29-65) 0.396
After Mph 52 (27-74) 52.5 (27-65) 55 (41-74) 0.542
Values are presented as median (range). 
COMT, catechol-O-methyltransferase; DLPFC, dorsolateral prefrontal cortex; ACC, anterior cingulate cortex; Mph, methylphenidate; NAA, 
N-acetylaspartate; Cho, choline; Cr, creatine.
By *Kruskal Wallis test and †two related sample test (Wilcoxon). 
Table 2. ADHD subtypes and the COMT gene polymorphism
COMT gene polymorphism
Val/val Val/met Met/met
Attention deficit type 9 (45.0) 8 (40.0) 3 (15.0)
Hyperactivity impulsivity type 5 (55.6) 3 (33.3) 1 (11.1)
Combined type 6 (21.4) 15 (53.6) 7 (25.0)
Total 20 (35.1) 26 (45.6) 11 (19.3)
Values are presented as number (%).
ADHD, attention deficit hyperactivity disorder; COMT, catechol-O- 
methyltransferase.
p=0.29, X 2=4.29; by chi-square test.
types according to COMT polymorphism (χ2=4.29, 
p=0.29; Table 2). In total, 37 of the males (82.2%) and 
nine of the females (75.0%) were val carriers, but there 
was no significant difference in the gender distribution ac-
cording to COMT polymorphism (χ2=0.31, p=0.57). 
For the metabolic assessments, the patients were cate-
gorized according to the COMT polymorphisms in two 
different ways, and all statistical analyses were performed 
accordingly. For the first categorization, the patients were 
divided into three groups (val/val, val/met, and met/met 
genotype carriers) and their neurometabolic variables 
were compared. For the second categorization, the pa-
tients were divided into two groups: val genotype carriers 
(val/val and val/met; i.e., rapid metabolizers) and met/met 
genotype carriers (slow metabolizers). After a single 
10-mg dose of Mph, there was a significant increase in 
NAA levels in the DLPFC of the val/val genotype carriers 
(p=0.04) and the ACC of the val carriers (p=0.03; Table 3 
and Fig. 1). The pre-Mph NAA/Cr ratio was significantly 
lower in the DLPFC of val carriers than that in the met/met 
genotype carriers (p=0.02), but there were no significant 
post-Mph alterations in NAA levels or NAA/Cr ratios in 
the other brain regions that were investigated. Cho levels 
in the striatum of the val/met and val genotype carriers sig-
nificantly increased after a single dose of Mph compared 
with pre-medication levels (p=0.01 and p=0.007, re-
spectively). However, there were no significant medi-
cation-related changes in Cho levels in the other brain re-
gions based on polymorphism (Table 3 and Fig. 1). 
Although the pre-medication Cr levels in the DLPFC were 
similar in all groups, after Mph treatment there were high-
er Cr levels in the met/met genotype carriers than in the 
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Fig. 2. Values of neurometabolites before and after methylphe-
nidate in met/met genotypes (slow metabolizers).
DLPFC, dorsolateral prefrontal cortex; ACC, anterior cingulate 
cortex; CB, cerebellum; STR, striatum; NAA, N-acetylaspartate; 
Cho, choline; Cr, creatinine.
*Before methylphenidate, 
†
after methylphenidate.
Fig. 1. Values of neurometabolites before and after methylphe-
nidate in Val carriers (rapid metabolizers).
DLPFC, dorsolateral prefrontal cortex; ACC, anterior cingulate 
cortex; CB, cerebellum; STR, striatum; NAA, N-acetylaspartate; 
Cho, choline; Cr, creatinine.
*Before methylphenidate, 
†
after methylphenidate.
val/met and val carriers (p=0.01 and p=0.03, respectively; 
Table 3). Consistent with these findings, the Cr levels in 
the DLPFC of the met/met genotype carriers significantly 
increased after a single dose of Mph compared with their 
pre-medication levels (p=0.01; Table 3 and Fig. 2). In the 
val/val genotype carriers, Cr levels in the striatum sig-
nificantly decreased after Mph treatment (p=0.01), but the 
Cr levels in the other brain regions were not affected 
(Table 3).
DISCUSSION
Of the 57 adult ADHD patients assessed in the present 
study, the number of rapid metabolizers (val carriers; 
n=46) was approximately fourfold higher than that of 
slow metabolizers (met/met genotype; n=11). The Val al-
lele enhances the hypo-dopaminergic state in the synaptic 
space to a greater degree than the Met allele due to its ther-
mostability,9) and healthy met/met genotype carriers ex-
hibit superior cognitive performance compared with 
val/val genotype carriers.12,13) Similarly, the Val allele has 
a stronger association with impaired working memory 
function than does the Met allele in healthy adults and 
children,14,15) and it is also associated with decreased pre-
frontal cortical activation in healthy adults.14) In contrast 
to these findings, other studies24,32) and meta-analyses22,23) 
have reported no relationship between ADHD and COMT 
gene polymorphisms. 
The predominance of val carriers in the present patient 
group appears to support the Val allele-ADHD relation-
ship in terms of disease etiology. The conflicting reports 
from several candidate gene studies may be due to the 
multigenic and multifactorial etiology of ADHD because, 
although the COMT polymorphism may affect the devel-
opment of ADHD, this does not occur in isolation. To bet-
ter understand this relationship, ADHD-related networks 
and other factors (particularly catecholamine-related 
polymorphisms) that may have an impact on the develop-
ment of ADHD should be researched on a larger scale. 
Consistent with the results of Yatsuga et al.,32) the present 
study did not find a relationship between ADHD subtype 
and COMT polymorphism. It is possible that the con-
tribution of the COMT polymorphism to ADHD is not 
subtype-specific or it could be that the small sample size 
used in the present study may have influenced the present 
results. 
NAA
Following treatment with Mph, there was a significant 
increase in the amount of NAA in the DLPFC of the 
val/val genotype carriers and in the ACC of the val 
carriers. In contrast, Carrey et al.33) did not find any sig-
nificant alterations in the neurometabolite levels in the 
right frontal region of ADHD patients after 13 weeks of 
treatment with atomoxetine, Mph, or Dexedrine. Husarova 
et al.25) reported that the NAA levels and NAA/Cr ratio de-
creased in the left DLPFC of ADHD patients after 2 
months of atomoxetine treatment, but that there were no 
significant alterations after treatment with Mph. A meta- 
analysis revealed that the amount of NAA in the medial 
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PFC of children with ADHD was significantly higher than 
that of the controls, but this difference declined with age 
and disappeared in adults, which suggests that age-related 
alterations in ADHD symptoms may have a neuronal 
basis.34)
In this respect, the present findings disagree with those 
of previous studies. NAA is considered to be a marker of 
regional neuronal activation and vitality,35) and neuro-
imaging studies conducted among ADHD patients have 
observed numerous alterations of this metabolite in vari-
ous brain regions, principally the PFC, ACC, and stria-
tum.36) Compared with healthy controls, ADHD patients 
show reduced perfusion, especially in the PFC,37,38) and a 
study investigating the effects of treatment on hypo-
perfusion found that stimulant medication increases blood 
flow in the bilateral prefrontal, caudate, and thalamic 
areas.38) Similarly, the chronic administration of Mph in-
creases neuronal mitochondrial activity in rats,39) and a 
single dose of Mph can lead to increases in neuronal acti-
vation in the frontal lobes of patients with ADHD.40)
Taken together, these data suggest that Mph has a pos-
itive impact on impaired cerebral perfusion and neuronal 
function. Therefore, post-Mph increases in NAA levels 
may indicate improved perfusion and increased neuronal 
activation, as in the present data. As suggested by Angelie 
et al.,41) the contrasting results among studies may be due 
to the presence or absence of a cognitive performance 
measure during the assessment process and, more im-
portantly, they may be related to age, sex, the investigated 
regions, or related variations in NAA levels.
NAA/Cr Ratio
In the present study, the pre-Mph NAA/Cr ratio in the 
DLPFC of val carriers was significantly lower than that of 
the met/met genotype carriers. During the literature search 
for this study, it became clear that no previous studies had 
investigated the relationship between the NAA/Cr ratio 
and COMT polymorphisms. Jin et al.42) reported a lower 
NAA/Cr ratio in the striatum of children with ADHD rela-
tive to that of healthy controls, and this did not change af-
ter a single 10-mg dose of Mph. In contrast, Fayed et al.43) 
found that the prefrontal cortico-subcortical NAA/Cr ratio 
is higher in ADHD children than in healthy controls, and 
Wiguna et al.44) reported a significantly increase in the 
NAA/Cr ratio in the bilateral PFC of ADHD patients after 
12 weeks of Mph treatment. Contradictory results in the 
literature may be due to changes in NAA levels according 
to age, sex, and the brain area investigated.
The NAA/Cr ratio is a marker of brain maturation.45) 
Childhood ADHD is related to delayed cortical matura-
tion, especially in the PFC.4) Furthermore, adult studies 
have demonstrated the presence of decreased gray matter 
and reduced cortical thickness in ADHD patients com-
pared with controls.46,47) It is known that cortical thickness 
is related to disease severity.47) The number of Val alleles 
in ADHD patients is associated with the rate at which DA 
is metabolized9-11) and, therefore, it is also related to dis-
ease severity. This indicates that the present finding that 
val carriers have a lower NAA/Cr ratio (a maturation 
marker) than the met/met genotype carriers is intuitive.
Cho
Cho levels significantly increased in the striatum of the 
val and val/met genotype carriers following treatment 
with Mph compared with pre-medication levels. To the 
best of our knowledge, no studies have investigated the re-
lationship between Cho levels in ADHD patients and 
COMT polymorphisms. A number of studies have as-
sessed Cho metabolites in ADHD patients and produced 
variable results. Similar to the present findings, Carrey et 
al.33) did not find any treatment-related changes in Cho 
levels in the PFC of ADHD children. However, this neg-
ative result in the striatal area contrasts with the findings 
of the present study. Kronenberg et al.48) found a sig-
nificant decrease in the Cho levels in the ACC of adult 
ADHD patients after 5-6 weeks of Mph treatment. In a 
study conducted by Amor,26) lower levels of Cho were re-
ported in the left prefrontal area of treatment-naïve 
ADHD patients compared with both treatment-receiving 
ADHD children and healthy controls. Jin et al.42) reported 
a marginal increase in the Cho/Cr ratio in the striatum of 
children with ADHD, but a single 10-mg dose of oral Mph 
had no effect on these ratios. The authors speculated that 
this could account for approximately 20-25% of the neural 
loss and/or dysfunction observed in ADHD patients. 
Cho is found in the cellular membrane and is an in-
dicator of lipid metabolism and membrane integrity.49) It 
should also be noted that Cho is an acetylcholine precursor 
that influences neural communication and is mediated by 
various neurotransmitters, including norepinephrine and 
DA. It has been suggested that impairments in dop-
aminergic pathways, as well as the imbalances in the dop-
aminergic-cholinergic system that are seen in ADHD, 
may affect Cho levels.42) With respect to previous studies, 
these differences may be related to medication type, treat-
ment duration and dose, and variations in the genetic 
structure of the recruited individuals. However, 57.9% of 
the present patients were medicated with Mph and, there-
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fore, the data may have been influenced by drug-induced 
effects on neuroplasticity. 
Cr
Following the administration of Mph in the present 
study, Cr levels in the DLPFC were significantly higher in 
the met/met genotype carriers than in the val/met geno-
type carriers and val carriers. In accordance with this re-
sult, Cr levels significantly increased in the DLPFC of 
met/met genotype carriers after Mph treatment compared 
with pre-Mph levels, whereas the striatal Cr levels in 
val/val genotype carriers significantly decreased after 
Mph treatment.
To the best of our knowledge, the Cr levels of ADHD 
patients have yet to be assessed according to COMT poly-
morphisms, and studies investigating variability in pre- 
and post-Mph Cr levels in ADHD patients have reported 
contrasting results. Yang et al.50) observed lower Cr and 
phospho-Cr levels in the right PFC of ADHD patients 
compared with healthy controls, whereas a meta-analysis 
revealed no difference in medial PFC Cr levels between 
ADHD and control groups.27) Consistent with the present 
results, Kronenberg et al.48) did not find any significant 
differences in pre- and post-treatment Cr levels in the 
ACC of adult ADHD patients after 5-6 weeks of Mph 
administration. 
Cr and phospho-Cr are accepted indicators of energy 
metabolism in neurons and astrocytes. Therefore, de-
creased levels of these parameters indirectly signify im-
paired neuronal activity and function.51) In the present 
study, val genotype carriers had lower prefrontal Cr levels 
than met/met genotype carriers, which supports the en-
ergetic hypothesis of ADHD49) and is consistent with the 
val amino acid-associated hypo-dopaminergic state ob-
served in ADHD patients.9) Following Mph treatment, 
there was a significant increase in Cr levels in the PFC of 
the met/met genotype carriers, which indicates that there 
was an increase in neuronal activity following treat-
ment-related improvements in hypoperfusion. In another 
study, baseline striatal Cr levels were reportedly higher in 
ADHD children than in controls after 8 weeks of treatment 
and, similar to the present findings, striatal Cr levels sig-
nificantly decreased.52) The authors speculated that stimu-
lant treatment might increase monoamine availability and 
striatal Cr within the context of a phospho-Cr-dependent 
uptake of glutamate into synaptic vesicles. Therefore, de-
creased post-medication Cr levels in the striatum may rep-
resent a compensatory mechanism.52)
It should be noted that approximately half the partic-
ipants in the present study had previously used Mph for 
the treatment of ADHD. Previous data have shown that 
chronic stimulant use influences the activities of neuro-
transmitter systems and brain plasticity, including syn-
aptic and non-synaptic levels.53,54) Despite contradictory 
findings,40,55) neuroimaging studies have demonstrated 
that Mph predominantly acts in the frontal cortex, basal 
ganglia (including the striatum), ACC, and cerebellum in 
ADHD patients and that psychostimulant medications 
generally normalize ADHD-related hypoactivation in 
these areas.54,55) Studies investigating the effects of psy-
chostimulants on the brains of ADHD patients indicate 
that these medications cause structural and developmental 
changes in important brain regions, such as the cerebellar 
vermis,56) ACC,57) and basal ganglia.58) Conversely, this 
type of medication is not related to the slowed growth of 
the cortical mantle in ADHD patients.59) Similarly, vol-
ume abnormalities in the cerebrum and cerebellum of 
ADHD patients are consistently identified across the 
childhood and adolescent periods, and these changes are 
not associated with medication use.60) In light of these da-
ta, it can be suggested that the present findings might have 
been affected by the previous use of Mph, even though 
Mph treatment was discontinued 48 hours prior to the neu-
roimaging to minimize its effect on neurometabolites. 
This may have prevented the identification of significant 
findings specifically related to the cerebellum due to the 
effects of chronic Mph use on the cerebellum. Thus, future 
studies are needed to evaluate the effects of Mph among 
ADHD patients who are drug-naïve.
It is also important to mention that neurometabolite lev-
els, particularly NAA, are affected by age27,41) and clinical 
presentation61) and that the neurobiological basis of 
ADHD changes with age.27,34) Therefore, the wide age 
range of the present sample may have affected the present 
results, which makes generalizing these findings difficult. 
There are several limitations to the present study. 
Approximately half the patients had already used Mph for 
the treatment of ADHD, and cigarette use, which may 
change the response to Mph, was not utilized as an ex-
clusion criterion. In the present study, a low Tesla MR 
scanner was used, and only unilateral brain assessments 
were conducted. Additionally, the sample size was rela-
tively small, no control group was included, and the wide 
age range of the patients decreases the generalizability of 
the results. Finally, although the patients were evaluated 
using adult ADD/ADHD DSM-IV-based diagnostic 
screening and rating scales prior to the administration of 
Mph, there were no assessments of treatment outcomes 
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following the administration of the drug.
The present study assessed the effects of single-dose 
Mph on three different neurometabolites in adult ADHD 
patients who were categorized according to COMT poly-
morphism. As expected, there was a predominance of val 
carriers (rapid metabolizers) among the patients. Pre- and 
post-medication changes in neurometabolite levels were 
detected in certain brain areas in accordance with COMT 
polymorphisms, which suggests that COMT gene poly-
morphisms can account for individual differences in the 
neurochemical response to Mph in ADHD patients. The 
present study provides important contributions to the liter-
ature, because it is the first to investigate the effects of sin-
gle-dose Mph on neurometabolite levels according to 
COMT polymorphisms.
To better understand the neuropathology of ADHD, 
further research using drug-naïve patients, larger sample 
sizes, and higher-resolution neuroimaging methods is 
required. Additionally, the effects of age and sex should be 
minimized, control groups should be included, and the 
specific effects of the COMT val158met polymorphism 
on treatment outcomes in ADHD patients should be 
analyzed.
The authors thank Ayse Gonca Unal for her contribution 
during the patient recruitment phase. 
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